Table 1.
Induction of CPE by the HEV-A strains.
| Serotype | Strain | Accession No. | L-bsd1 | L-PSGL-1.1 | L-Empty2,3 | L-SCARB23 |
|---|---|---|---|---|---|---|
| CVA2 | Fleetwood | AY421760 | − | − | − | − |
| CVA3 | Olson | AY421761 | − | − | − | − |
| CVA4 | JR4 | AB457644 | − | − | − | − |
| CVA5 | Swartz | AY421763 | − | − | − | − |
| CVA6 | Gdula | AY421764 | − | − | − | − |
| CVA7 | Parker | AY421765 | − | + | + | + |
| CVA8 | Donovan | AY421766 | − | − | − | − |
| CVA10 | Kowalik | AY421767 | + | + | + | + |
| CVA12 | Texas-12 | AY421768 | − | − | − | − |
| CVA14 | G-14 | AY421769 | − | + | + | + |
| CVA16 | G-10 | U05876 | − | + | − | + |
1Blasticidin-resistant L929 cells (a negative control for L-PSGL-1.1 cells).
2Puromycin-resistant L929 cells (a negative control for L-SCARB2 cells).
3Yamayoshi et al. (2009).
4Prototype CVA4 strain (high point) is unavailable from ATCC, therefore we used an in-house reference strain of CVA4, the JR strain.